Femasys Inc. (FEMY)

NCM – Цена в реальном времени. Валюта: USD

0.38

-0.03 (-6.70%)

При закрытии: May 12, 2026, 4:00 PM EDT

0.39

+0.01 (2.36%)

До открытия: May 13, 2026, 9:18 AM EDT

08.05.2026

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

-- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices --

05.05.2026

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

-- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting, led by FemaSeed as a first-line infertility treatment. The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and outcomes.

31.03.2026

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

-- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval --

27.02.2026

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has granted to two new non-executive employees who began their employment with Femasys in February 2026 options to purchase 185,000 shares of Femasys common stock.

23.02.2026

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to this first-step infertility treatment option.

13.01.2026

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient population

18.12.2025

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

-- Innovative single-device solution integrates proven FemVue and FemChec ® technologies to support fallopian tube evaluation and improve workflow efficiency-- ATLANTA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its FemVue Controlled device, an innovative diagnostic solution designed for controlled contrast delivery to evaluate fallopian tube status. The next-generation FemVue Controlled device integrates features of the Company's original FemVue and FemChec technologies into a single FDA-cleared product, enabling multiple clinical uses while streamlining manufacturing and practice workflows.

Видео

No Data

There is no data to display

Пресс-релизы

08.05.2026

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

05.05.2026

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

31.03.2026

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

27.02.2026

Femasys Inc. (FEMY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Femasys Inc. (FEMY)

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Видео

No Data

Пресс-релизы

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Видео

No Data

Пресс-релизы

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Femasys Inc. (FEMY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Femasys Inc. (FEMY)

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Видео

No Data

Пресс-релизы

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

Видео

No Data

Пресс-релизы

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)